Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Abdominal Neoplasms 1

Interventions

pembrolizumab 45Paclitaxel 45Carboplatin 39Magnetic Resonance Spectroscopy 28olaparib 27Specimen Handling 26Cisplatin 24Bevacizumab 20Nivolumab 18Taxes 17Biopsy 16Gemcitabine 13Cyclophosphamide 13durvalumab 12Immunoglobulin G 11Doxorubicin 11Disulfides 11Surveys and Questionnaires 10niraparib 9liposomal doxorubicin 9dostarlimab 9Radiotherapy 8Brachytherapy 8lenvatinib 7fludarabine 7atezolizumab 7Letrozole 7Docetaxel 7cediranib 6Platinum 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Cell Count × Gynecologic × Clear all
NCT05617755 2025-07-30

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Arsenal Biosciences, Inc.

Phase 1 Active not recruiting
19 enrolled
Gynecologic

Abdominal Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡